Patients with myasthenia gravis experience higher comorbidity rates and healthcare utilization compared to healthy controls, indicating a significant disease burden. Treatment patterns for myasthenia ...

A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...

SAVANNAH, Ga. -- Investigational nipocalimab plus standard of care achieved sustained reductions in immunoglobulin G (IgG) and appeared to be safe for adolescent patients with generalized myasthenia ...

Former tennis star Monica Seles recently revealed she is living with the rare disease myasthenia gravis, which affects 12 in 100,000 people globally. Seles explained her first symptoms appeared ...

First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied About 10% ...

Tennis legend Monica Seles is opening up about her journey with myasthenia gravis, a neuromuscular autoimmune disease she was diagnosed with three years ago. In a recent interview with The Associated ...

The MarketWatch News Department was not involved in the creation of this content. New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug ...

The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and ...

Please provide your email address to receive an email when new articles are posted on . Nipocalimab led to significant improvements in disease-specific metrics from baseline among patients with ...

WASHINGTON — Monica Seles first noticed the symptoms of myasthenia gravis — a neuromuscular autoimmune disease she discussed during a recent interview with The Associated Press — while she was ...

New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the ...